Pharma & Biotech Global Week in Review 21 October 2009 from IP Think Tank

Here is IP Think Tank’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: http://thinkipstrategy.com/subscribe/

 
Highlights this week included:

US: Senate Judiciary Committee passes bill against “pay for delay” drug settlements (Prior Art) (Patently-O) (Patent Docs)

Valcyte (Valganciclovir) – US: District Court New Jersey finds Roche’s Valcyte patent valid and not infringed by Ranbaxy (Patent Docs) (GenericsWeb)

 
General

Médecins Sans Frontiéres calls on drug companies to pool HIV patents (Patent Docs) (IP Osgoode)

Medicines for Rwanda but what about the “drug miles”? (Afro-IP)

200,000 die annually because of fake malaria medicine – Smithsonian article ‘The Fatal Consequences of Counterfeit Drugs’ (Innovationpartners)

‘Translational medicine’ (IPKat)

Brazil: Brazilian Ministry of Health calls for partnerships between public laboratories and private companies (IP tango)

Brazil: Rio 2016 – who will pay and how? – response to IAM article suggesting pharmaceutical companies will subsidise Rio 2016 (IP tango)

EU: India, Brazil to file WTO complaint against the EU over ‘seizures’ of pharma drug consignments (Spicy IP)

US: PhRMA supports follow-on biologics regulatory pathway providing 12 years of data exclusivity (Patent Docs)

US: Senators Orrin Hatch, Barbara Mikulski, Michael Enzi and Kay Hagan write in support of 12-year data exclusivity period (Patent Docs)

US: New England Journal of Medicine say five years of data exclusivity would be sufficient (Patent Docs)

US: Maybe Hatch-Waxman data exclusivity isn’t so good for traditional drugs after all (Patent Docs)

US: Senators introduce access to affordable medicines act to close labelling change “loophole”; Companion Bill to Senate Drug Price Competition Act of 2009 – Introduced in House (FDA Law Blog)

US: Senate Judiciary Committee passes bill against “pay for delay” drug settlements (Prior Art) (Patently-O) (Patent Docs)

US: Dr Tafas files reply to USPTO/GSK motion to dismiss appeal and vacate district Court judgment – Tafas v Kappos (Patent Docs)

US: Chugai Seiyaku Kabushiki Kaisha files suit seeking review and correction of patent term adjustment calculation (Patent Docs)

US: Be all you can’t be: Army patent ambushed by friendly fire (12:01 Tuesday)

US: Patentable subject matter: Federal Circuit upholds patentability of drug dosage method claim – Prometheus Labs v Mayo Clinic (Patently-O) (Patently-O)

US: Declaratory Judgment standing – must all patent owners be joined? In re KGK Synergize (non precedential) (Patently-O)

US: Myriad sticks to its business model despite legal action brought by PUBPAT and others: Association for Molecular Pathology v USPTO (Patent Docs)

US: Amazing race: Win $250,000 for commercialising biomedical research (Patent Baristas)

US: BIO survey on technology transfer shows complexity of university-industry relationships (PatentBIOtech)

 
Products

Adderall (Dextroamphetamine, Amphetamine) – US: Shire announces settlement with Sandoz over Adderall (Patent Docs) (GenericsWeb)

Allegra (Fexofenadine) – US: Aventis files patent infringement suit against Sun Pharmaceuticals following Para IV challenge (Patent Docs)

Angiomax (Bivalirudin) – Medicines Co files patent infringement suits against Teva and AAP following Para IV certification as part of Teva’s ANDA to manufacture generic Angiomax (Patent Docs)

Atripla, Truvada (Tenofovir, Emcitrabine) – US: Teva files counterclaims of patent invalidity in Gilead suit – Gilead Sciences Inc v Teva Pharmaceuticals (Patent Docs)

Copaxone (Glatiramer acetate) – US: Teva files patent infringement suit against Mylan in response to Para IV filing (PatLit) (SmartBrief) (IP Factor)

Cozaar (Losartan) – Denmark: Losartan and Caspofungin granted paediatric extensions (The SPC blog)

Duac (Clindamycin, Benzoyl peroxide) – US: Perrigo announces dismissal with prejudice of Hatch-Waxman litigation relating to Duac filed by Stiefel (GenericsWeb)

Efudex (Fluorouracil) – US: FDA racks up another win in bioequivalence litigation; this time over generic Efudex (FDA Law Blog)

Evista (Raloxifene), Xigris (Drotrecogin alfa) – US: Amici briefs in Ariad v Lilly (Holman’s Biotech IP Blog) (Patently-O)

Fabrazyme (Agalsidase beta) – US: Shelbyzyme files patent infringement suit against Genzyme over manufacture and sale of Fabrazyme(Patent Docs)

Gemzar (Gemcitabine) – US: Eli Lilly files patent infringement suit against Sandoz following Para IV challenge(Patent Docs)

Rogaine (Minoxidil) – US: Steifel files patent infringement suit against Perrigo following Para IV challenge (Patent Docs)

Valcyte (Valganciclovir) – US: District Court New Jersey finds Roche’s Valcyte patent valid and not infringed by Ranbaxy (Patent Docs) (GenericsWeb)

Vfend (Voriconazole) – US: Pfizer announces settlement and license agreement with Mylan related to Vfend (SmartBrief) (SmartBrief)

 

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: